Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. (CURA.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cura.to · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $15.69
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $16.14 | ↑ 2.87% |
1-day model range: $15.99–$16.29. Peak: $16.29 (+2.87%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $10 | -33.2% |
| 2028 | $8 | -46.5% |
| 2029 | $7 | -52.9% |
| 2030 | $7 | -56.3% |
| 2031 | — | -58.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CURA.TO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-08-08 | Needham | Maintains | Buy→Buy |
| 2024-05-10 | Needham | Maintains | Buy→Buy |
| 2024-03-08 | Wedbush | Maintains | Outperform→Outperform |
| 2024-03-07 | Craig-Hallum | Maintains | Hold→Hold |
| 2024-03-07 | Needham | Maintains | Buy→Buy |
| 2023-08-10 | Needham | Maintains | Buy→Buy |
| 2023-05-19 | Benchmark | Downgrade ↓ | Buy→Hold |
| 2023-05-19 | Wedbush | Maintains | Outperform→Outperform |
| 2023-05-18 | Needham | Maintains | Buy→Buy |
| 2023-05-02 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Curaleaf Holdings, Inc. (CURA.TO) stock. Of the recent 36 rating actions, 1 were upgrades and 1 were downgrades. 7 analysts currently cover CURA.TO.
Analyst Recommendation Trends
CURA.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1.3B
↓ 15.8% YoY
Revenue Next Year
$1.4B
↑ 8.1% YoY
EPS This Year
$-0.09
EPS Next Year
$-0.17
↑ 91.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CURA.TO EPS of $-0.09 for the current fiscal year, based on estimates from 2 analysts. The CURA.TO revenue forecast is $1.3B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CURA.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CURA.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The CURA.TO short-term stock prediction for tomorrow is $16.14 (+2.87%). The CURA.TO stock price prediction for 2027 estimates an average of $10. The CURA.TO stock prediction for 2030 projects a range of $6–$8.
Curaleaf Holdings, Inc. trades on TSX under the ticker CURA.TO. The CURA.TO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
CURA.TO forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CURA.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $15.69.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.